OPDIVO with You means just that: we’re here to help you better understand OPDIVO, whether you or a loved one are just considering OPDIVO or already have an OPDIVO prescription. This complimentary program includes the following resources.

Support Resources Icon
Support Resources Icon

Helpful Information

Get useful tips, tools, and educational materials that can help you learn more about OPDIVO® and may help support your care.

 
Personalized Care Counselor Support Icon

Support and Advocacy Groups

We can direct you to organizations that maybe helpful for the challenges you may face.

Support Resources Icon

A Care Counselor as Close as Your Phone

If you are prescribed OPDIVO and sign up for this additional resource, you'll be able to speak with a registered nurse. This personal Care Counselor can answer questions about treatment and help you to be a more informed partner with your doctor. Care Counselors cannot provide medical advice. Your healthcare professional is the best source of information about your health.

 

If you’d like to sign up for the OPDIVO with YOU program or if you have general questions about OPDIVO,
call 1-855-OPDIVO-1
(1-855-673-4861) 8 AM to 8 PM ET, Monday to Friday, or click the button to sign up.












Tell us about yourself

 

Your Details

 

Diagnosis and Treatment

 
 

Care Counselor Support

 
 

Your Oncologist

 
 
The information you’ve provided us may be used by Bristol-Myers Squibb, or parties acting on its behalf, to contact you via mail, telephone, in electronic format, or otherwise in the future for market research, clinical trials, and other information and offers that it believes to be of interest to you. This information may be provided to other parties that Bristol-Myers Squibb is working with, including but not limited to its subsidiaries and affiliates, in order to help develop programs and provide services that may be of interest to you, provide educational information, or for processing, mailing, and/or Internet-based delivery purposes. <span class="noBr">Bristol-Myers Squibb</span> may also use your information for communication, services, and marketing activities. From time to time the Privacy Policy may change and for the most recent version you should <a target="_blank" href="http://www.bms.com/legal/Pages/privacy.aspx">click here</a>.<br> <br>You can stop future marketing communications and use of your information by calling <span class="noBr"><span class='desktop_show'>1-855-OPDIVO (1-855-673-4861)</span><a class='desktop_hide' target="_blank" href="tel:(1-855-673-4861)">1-855-OPDIVO (1-855-673-4861)</a></span>.

More Important Safety Information

 

INDICATIONS

For Patients Previously Treated with Advanced Non-Small Cell Lung Cancer (1 of 6)

OPDIVO® (nivolumab) is a prescription medicine used to treat a type of advanced stage lung cancer (called non-small cell lung cancer) that has spread or grown and you have tried chemotherapy that contains platinum, and it did not work or is no longer working. If your tumor has an abnormal EGFR or ALK gene, you should have also tried an FDA-approved therapy for tumors with these abnormal genes, and it did not work or is no longer working.

For Patients with Metastatic Melanoma (2 of 6)

OPDIVO® (nivolumab) is a prescription medicine used to treat a type of skin cancer called melanoma that has spread or cannot be removed by surgery (advanced melanoma). OPDIVO is approved for both BRAF+ and BRAF- patients. OPDIVO was approved for BRAF+ metastatic melanoma patients based on the amount of time patients lived without their tumors worsening. There is ongoing evaluation of clinical benefit of OPDIVO for this use.

OPDIVO® (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) to treat a type of skin cancer called melanoma that has spread or cannot be removed by surgery (advanced melanoma). OPDIVO in combination with YERVOY was approved based on the amount of time patients lived without their tumors worsening. There is ongoing evaluation of clinical benefit of OPDIVO in combination with YERVOY for this use.

OPDIVO (10 mg/mL) and YERVOY (5 mg/mL) are injections for intravenous (IV) use.

For Previoulsy Treated Patients with Advanced Renal Cell Carcinoma (3 of 6)

OPDIVO® (nivolumab) is a prescription medicine used to treat kidney cancer (renal cell carcinoma) when your cancer has spread or grown after treatment with other cancer medications.

For Adults with cHL Whose Cancer Has Come Back or Spread After an Autologous Stem Cell Transplant and Were Treated With Adcetris® (brentuximab vedotin) (4 of 6)

OPDIVO® (nivolumab) is a prescription medicine used to treat adults with a type of blood cancer called classical Hodgkin Lymphoma if your cancer has come back or spread after a type of stem cell transplant that uses your own stem cells (autologous), and you used the drug brentuximab vedotin (Adcetris®) before or after your stem cell transplant, or if you received at least 3 kinds of treatment including an autologous stem cell transplant. OPDIVO was approved based on response rate. There is ongoing evaluation of clinical benefit of OPDIVO for this use.

For Adults with Squamous Cell Carcinoma of the Head and Neck (SCCHN) That Has Returned or Spread After Previous Treatment (5 of 6)

OPDIVO® (nivolumab) is a prescription medicine used to treat head and neck cancer (squamous cell carcinoma) that has come back or spread and you have tried chemotherapy that contains platinum and it did not work or is no longer working.

For Adults with Previously Treated Advanced Bladder Cancer (Urothelial Carcinoma) (6 of 6)

OPDIVO® (nivolumab) is a prescription medicine used to treat bladder cancer (urothelial carcinoma) that has spread or grown and you have tried chemotherapy that contains platinum, and it did not work or is no longer working. OPDIVO was approved based on response rate and how long patients' responses lasted. There is ongoing evaluation of clinical benefit of OPDIVO for this use.

It is not known if OPDIVO is safe and effective in children less than 18 years of age.

Important Safety Information
for OPDIVO® (nivolumab)

and the OPDIVO +
YERVOY® (ipilimumab) Regimen

OPDIVO is a medicine that may treat your melanoma, lung cancer, kidney cancer, blood cancer, head and neck cancer, or bladder cancer by working with your immune system. OPDIVO can cause your immune system to attack normal organs and tissues in many areas of your body and can affect the way they work. These problems can sometimes become serious or life-threatening and can lead to death. These problems may happen anytime during treatment or even after your treatment has ended. Some of these problems may happen more often when OPDIVO is used in combination with YERVOY.

YERVOY can cause serious side effects in many parts of your body which can lead to death. These problems may happen anytime during treatment with YERVOY or after you have completed treatment.

Serious side effects may include:

  • Lung problems (pneumonitis). Symptoms of pneumonitis may include: new or worsening cough; chest pain; and shortness of breath.
  • Intestinal problems (colitis) that can lead to tears or holes in your intestine. Signs and symptoms of colitis may include: diarrhea (loose stools) or more bowel movements than usual; blood in your stools or dark, tarry, sticky stools; and severe stomach area (abdomen) pain or tenderness.
  • Liver problems (hepatitis). Signs and symptoms of hepatitis may include: yellowing of your skin or the whites of your eyes; severe nausea or vomiting; pain on the right side of your stomach area (abdomen); drowsiness; dark urine (tea colored); bleeding or bruising more easily than normal; and feeling less hungry than usual.
  • Hormone gland problems (especially the thyroid, pituitary, adrenal glands, and pancreas). Signs and symptoms that your hormone glands are not working properly may include: headaches that will not go away or unusual headaches; extreme tiredness; weight gain or weight loss; dizziness or fainting; changes in mood or behavior, such as decreased sex drive, irritability, or forgetfulness; hair loss; feeling cold; constipation; voice gets deeper; and excessive thirst or lots of urine.
  • Kidney problems, including nephritis and kidney failure. Signs of kidney problems may include: decrease in the amount of urine; blood in your urine; swelling in your ankles; and loss of appetite.
  • Skin problems. Signs of these problems may include: rash; itching; skin blistering; and ulcers in the mouth or other mucous membranes.
  • Inflammation of the brain (encephalitis). Signs and symptoms of encephalitis may include: headache; fever; tiredness or weakness; confusion; memory problems; sleepiness; seeing or hearing things that are not really there (hallucinations); seizures; and stiff neck.
  • Problems in other organs. Signs of these problems may include: changes in eyesight; severe or persistent muscle or joint pains; and severe muscle weakness.

Additional serious side effects observed during a separate study of YERVOY alone include:

  • Nerve problems that can lead to paralysis. Symptoms of nerve problems may include: unusual weakness of legs, arms, or face; and numbness or tingling in hands or feet.
  • Eye problems. Symptoms may include: blurry vision, double vision, or other vision problems; and eye pain or redness.

Getting medical treatment right away may keep these problems from becoming more serious.

Your healthcare provider will check you for these problems during treatment. Your healthcare provider may treat you with corticosteroid or hormone replacement medicines. Your healthcare provider may also need to delay or completely stop treatment, if you have severe side effects.

OPDIVO can cause serious side effects, including:

  • Severe infusion reactions. Tell your doctor or nurse right away if you get these symptoms during an infusion of OPDIVO: chills or shaking; itching or rash; flushing; difficulty breathing; dizziness; fever; and feeling like passing out.
  • Complications of stem cell transplant that uses donor stem cells (allogeneic) after treatment with OPDIVO. These complications can be severe and can lead to death. Your healthcare provider will monitor you for signs of complications if you have an allogeneic stem cell transplant.

Pregnancy and Nursing:

  • Tell your healthcare provider if you are pregnant or plan to become pregnant. OPDIVO and YERVOY can harm your unborn baby. Females who are able to become pregnant should use an effective method of birth control during and for at least 5 months after the last dose of OPDIVO. Talk to your healthcare provider about birth control methods that you can use during this time. Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment. You or your healthcare provider should contact Bristol-Myers Squibb at
    1-800-721-5072 as soon as you become aware of the pregnancy.
  • Pregnancy Safety Surveillance Study: Females who become pregnant during treatment with YERVOY are encouraged to enroll in a Pregnancy Safety Surveillance Study. The purpose of this study is to collect information about the health of you and your baby. You or your healthcare provider can enroll in the Pregnancy Safety Surveillance Study by calling 1-844-593-7869.
  • Before receiving treatment, tell your healthcare provider if you are breastfeeding or plan to breastfeed. It is not known if either treatment passes into your breast milk. Do not breastfeed during treatment and for 3 months after the last dose of YERVOY.

Tell your healthcare provider about:

  • Your health problems or concerns if you: have immune system problems such as autoimmune disease, Crohn’s disease, ulcerative colitis, lupus, or sarcoidosis; have had an organ transplant; have lung or breathing problems; have liver problems; or have any other medical conditions.
  • All the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

The most common side effects of OPDIVO when used alone include: feeling tired; pain in muscles, bones, and joints; diarrhea; cough; constipation; back pain; fever; rash; itchy skin; nausea; shortness of breath; decreased appetite; upper respiratory tract infection; and weakness.

The most common side effects of OPDIVO, when used in combination with YERVOY include: feeling tired; diarrhea; fever; shortness of breath; rash; nausea; and vomiting. The most common side effects of YERVOY include: tiredness; diarrhea; itching; rash; nausea; vomiting; headache; weight loss; fever; decreased appetite; and difficulty falling or staying asleep.

These are not all the possible side effects. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to Bristol-Myers Squibb at
1-800-721-5072.

INDICATIONS

For Patients Previously Treated with Advanced Non-Small Cell Lung Cancer (1 of 6)

OPDIVO® (nivolumab) is a prescription medicine used to treat a type of advanced stage lung cancer (called non-small cell lung cancer) that has spread or grown and you have tried chemotherapy that contains platinum, and it did not work or is no longer working. If your tumor has an abnormal EGFR or ALK gene, you should have also tried an FDA-approved therapy for tumors with these abnormal genes, and it did not work or is no longer working.

For Patients with Metastatic Melanoma (2 of 6)

OPDIVO® (nivolumab) is a prescription medicine used to treat a type of skin cancer called melanoma that has spread or cannot be removed by surgery (advanced melanoma). OPDIVO is approved for both BRAF+ and BRAF- patients. OPDIVO was approved for BRAF+ metastatic melanoma patients based on the amount of time patients lived without their tumors worsening. There is ongoing evaluation of clinical benefit of OPDIVO for this use.

OPDIVO® (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) to treat a type of skin cancer called melanoma that has spread or cannot be removed by surgery (advanced melanoma). OPDIVO in combination with YERVOY was approved based on the amount of time patients lived without their tumors worsening. There is ongoing evaluation of clinical benefit of OPDIVO in combination with YERVOY for this use.

OPDIVO (10 mg/mL) and YERVOY (5 mg/mL) are injections for intravenous (IV) use.

For Previoulsy Treated Patients with Advanced Renal Cell Carcinoma (3 of 6)

OPDIVO® (nivolumab) is a prescription medicine used to treat kidney cancer (renal cell carcinoma) when your cancer has spread or grown after treatment with other cancer medications.

For Adults with cHL Whose Cancer Has Come Back or Spread After an Autologous Stem Cell Transplant and Were Treated With Adcetris® (brentuximab vedotin) (4 of 6)

OPDIVO® (nivolumab) is a prescription medicine used to treat adults with a type of blood cancer called classical Hodgkin Lymphoma if your cancer has come back or spread after a type of stem cell transplant that uses your own stem cells (autologous), and you used the drug brentuximab vedotin (Adcetris®) before or after your stem cell transplant, or if you received at least 3 kinds of treatment including an autologous stem cell transplant. OPDIVO was approved based on response rate. There is ongoing evaluation of clinical benefit of OPDIVO for this use.

For Adults with Squamous Cell Carcinoma of the Head and Neck (SCCHN) That Has Returned or Spread After Previous Treatment (5 of 6)

OPDIVO® (nivolumab) is a prescription medicine used to treat head and neck cancer (squamous cell carcinoma) that has come back or spread and you have tried chemotherapy that contains platinum and it did not work or is no longer working.

For Adults with Previously Treated Advanced Bladder Cancer (Urothelial Carcinoma) (6 of 6)

OPDIVO® (nivolumab) is a prescription medicine used to treat bladder cancer (urothelial carcinoma) that has spread or grown and you have tried chemotherapy that contains platinum, and it did not work or is no longer working. OPDIVO was approved based on response rate and how long patients' responses lasted. There is ongoing evaluation of clinical benefit of OPDIVO for this use.

It is not known if OPDIVO is safe and effective in children less than 18 years of age.

Please see U.S. Full Prescribing Information, including Boxed WARNING regarding immune-mediated side effects, and Medication Guide for YERVOY.

Please see U.S. Full Prescribing Information and Medication Guide for OPDIVO.

Information provided in this website is not a substitute for talking with your healthcare professional. Your healthcare professional is the best source of information about your disease.

All individuals depicted are models used for illustrative purposes only.

Bristol-Myers Squibb Logo

Legal Notice | Privacy Policy

© 2017 Bristol-Myers Squibb Company.
All rights reserved.
OPDIVO®, YERVOY®, and the related
logos are trademarks of
Bristol-Myers Squibb Company.
Adcetris® is a registered trademark of
Seattle Genetics, Inc.

1506US1604025-04-01 05/17

This link is currently not available.
Please check back at a later time.

You are about to leave this Bristol-Myers Squibb
Company site.
You are being redirected to another
Bristol-Myers Squibb Company site.

Would you like to leave this site?

Yes

No

You are now leaving this Bristol-Myers Squibb site.

This Internet site may provide links or references to other sites. BMS has no responsibility for the content of such other sites and is not liable for any damages or injury arising from that content. Any links to other sites are provided merely as a convenience to the users of this Internet site.

 

This link is currently not available.
Please check back at a later time.

CLOSE